David G. Parr

TL;DR: The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers.

TL;DR: It is crucial to organise national and international registries and collect information prospectively about the natural history of the disease, as AATD is a rare disease and inequalities in access to therapies across Europe should be addressed.

TL;DR: Findings indicate that CT detectable structural changes in the lung of COPD patients, which are termed severe subtypes, are associated with alterations in bacterial communities, which may induce further changes inThe interaction between microbes and host cells and result in a changed interplay with the host immune system.

TL;DR: A meta-analysis showed that 35.0% (95% CI 22.2-48.9%) of women with PCOS had obstructive sleep apnoea (OSA) as mentioned in this paper.

TL;DR: No significant associations were observed between lung transcriptional signals from bronchial brushings and abundance of bacterial genera in patients with COPD without inhaled corticosteroids treatment and in healthy individuals, but Prevotella abundance was inversely related to COPD severity in terms of symptoms and positively related to lung function and exercise capacity.